JP2021517813A5 - - Google Patents
Info
- Publication number
- JP2021517813A5 JP2021517813A5 JP2020548778A JP2020548778A JP2021517813A5 JP 2021517813 A5 JP2021517813 A5 JP 2021517813A5 JP 2020548778 A JP2020548778 A JP 2020548778A JP 2020548778 A JP2020548778 A JP 2020548778A JP 2021517813 A5 JP2021517813 A5 JP 2021517813A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- modified
- antigen
- adjuvant
- input
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024188260A JP2025020210A (ja) | 2018-03-12 | 2024-10-25 | 免疫応答を改変するための生体分子の細胞内送達 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862641987P | 2018-03-12 | 2018-03-12 | |
| US62/641,987 | 2018-03-12 | ||
| US201862738941P | 2018-09-28 | 2018-09-28 | |
| US62/738,941 | 2018-09-28 | ||
| US201962794516P | 2019-01-18 | 2019-01-18 | |
| US62/794,516 | 2019-01-18 | ||
| PCT/US2019/021705 WO2019178006A2 (en) | 2018-03-12 | 2019-03-11 | Intracellular delivery of biomolecules to modify immune response |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024188260A Division JP2025020210A (ja) | 2018-03-12 | 2024-10-25 | 免疫応答を改変するための生体分子の細胞内送達 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021517813A JP2021517813A (ja) | 2021-07-29 |
| JP2021517813A5 true JP2021517813A5 (enExample) | 2022-03-18 |
| JP7595827B2 JP7595827B2 (ja) | 2024-12-09 |
Family
ID=66102189
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020548778A Active JP7595827B2 (ja) | 2018-03-12 | 2019-03-11 | 免疫応答を改変するための生体分子の細胞内送達 |
| JP2024188260A Pending JP2025020210A (ja) | 2018-03-12 | 2024-10-25 | 免疫応答を改変するための生体分子の細胞内送達 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024188260A Pending JP2025020210A (ja) | 2018-03-12 | 2024-10-25 | 免疫応答を改変するための生体分子の細胞内送達 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20240374654A2 (enExample) |
| EP (1) | EP3765068A2 (enExample) |
| JP (2) | JP7595827B2 (enExample) |
| KR (1) | KR20200130835A (enExample) |
| CN (1) | CN112135627A (enExample) |
| AU (2) | AU2019234550B2 (enExample) |
| BR (1) | BR112020018612A2 (enExample) |
| CA (1) | CA3093828A1 (enExample) |
| CO (1) | CO2020012584A2 (enExample) |
| CR (1) | CR20200460A (enExample) |
| IL (1) | IL277188B2 (enExample) |
| MA (1) | MA52010A (enExample) |
| MX (1) | MX2020009439A (enExample) |
| PH (1) | PH12020551436A1 (enExample) |
| SG (1) | SG11202008864VA (enExample) |
| TW (1) | TW202003019A (enExample) |
| WO (1) | WO2019178006A2 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3344575B1 (en) | 2015-09-04 | 2020-04-15 | SQZ Biotechnologies Company | Intracellular delivery of biomolecules to cells comprising a cell wall |
| CA3023092A1 (en) | 2016-05-03 | 2017-11-09 | Sqz Biotechnologies Company | Intracellular delivery of biomolecules to induce tolerance |
| AU2019234549B2 (en) | 2018-03-12 | 2026-02-12 | Sqz Biotechnologies Company | Methods for treating HPV-associated diseases |
| JP7340591B2 (ja) * | 2018-07-11 | 2023-09-07 | アクティム・セラピューティクス・インコーポレイテッド | 遺伝子操作された免疫刺激性細菌菌株およびその使用 |
| JP6884450B2 (ja) * | 2019-02-14 | 2021-06-09 | 学校法人獨協学園獨協医科大学 | Ｔ細胞ワクチン |
| CA3131701A1 (en) | 2019-02-28 | 2020-09-03 | Sqz Biotechnologies Company | Delivery of biomolecules to pbmcs to modify an immune response |
| KR20210149791A (ko) | 2019-04-08 | 2021-12-09 | 에스큐지 바이오테크놀로지스 컴퍼니 | 페이로드를 세포 내로 전달하기 위한 시스템에서 이용하기 위한 카트리지 |
| JP2023527690A (ja) | 2020-05-11 | 2023-06-30 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 改変ｐｂｍｃと免疫抱合体との併用療法 |
| KR20230058388A (ko) | 2020-07-29 | 2023-05-03 | 에스큐지 바이오테크놀로지스 컴퍼니 | 무핵 세포를 사용해 돌연변이체 ras에 대한 면역 반응을 자극하는 방법 |
| US20250255961A1 (en) | 2020-07-29 | 2025-08-14 | Stemcell Technologies Canada Inc. | Methods to stimulate immune responses to mutant ras using nucleated cells |
| US20220296691A1 (en) | 2020-12-29 | 2022-09-22 | Sqz Biotechnologies Company | Methods for treating cancer with activating antigen carriers |
| EP4271407A1 (en) | 2020-12-29 | 2023-11-08 | SQZ Biotechnologies Company | Formulations of activating antigen carriers |
| US12150982B2 (en) | 2020-12-29 | 2024-11-26 | Stemcell Technologies Canada Inc. | Formulations of PBMCs |
| EP4271711A1 (en) | 2020-12-29 | 2023-11-08 | SQZ Biotechnologies Company | Methods for treating cancers with modified pbmcs |
| CN115252772A (zh) * | 2021-04-30 | 2022-11-01 | 华普生物技术(江苏)股份有限公司 | 人工合成的含CpG单链脱氧寡核苷酸在疫苗中的应用 |
| US20250327027A1 (en) | 2021-07-29 | 2025-10-23 | Stemcell Technologies Canada Inc. | Methods to generate enhanced tumor infiltrating lymphocytes through microfluidic delivery |
| JP2024545582A (ja) | 2021-11-11 | 2024-12-10 | ステムセル テクノロジーズ カナダ インコーポレイテッド | マイクロ流体送達による増強された腫瘍浸潤リンパ球を作製する方法 |
| WO2024026491A2 (en) | 2022-07-28 | 2024-02-01 | Sqz Biotechnologies Company | Enhanced antigen presenting cell formulations |
| EP4561620A1 (en) | 2022-07-28 | 2025-06-04 | Stemcell Technologies Canada Inc. | Methods for treating cancer with enhanced antigen presenting cells |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003290460A1 (en) * | 2003-12-24 | 2005-07-14 | Leiden University Medical Center | Synthetic protein as tumor-specific vaccine |
| MX2009012922A (es) * | 2007-05-31 | 2010-07-05 | Academisch Ziekenhuis Leiden H | Vacunacion intradermica de un peptido del virus del papiloma humano. |
| WO2009039125A1 (en) * | 2007-09-17 | 2009-03-26 | The Schepens Eye Research Institute, Inc. | Use of ocular neuropeptides as immune adjuvants |
| CA3017298C (en) * | 2009-05-15 | 2021-09-28 | Irx Therapeutics, Inc. | Compositions comprising primary cell-derived biologics for enhancing immune responses in patients |
| PT2768942T (pt) * | 2011-10-17 | 2020-01-21 | Massachusetts Inst Technology | Entrega intracelular |
| US20170212116A1 (en) * | 2014-01-31 | 2017-07-27 | Ulisse Biomed Srl | Biosensors for the detection of infection and associated maladies |
| KR20170074235A (ko) * | 2014-10-31 | 2017-06-29 | 메사추세츠 인스티튜트 오브 테크놀로지 | 면역 세포로의 생체분자의 전달 |
| PL3344747T3 (pl) | 2015-09-04 | 2023-06-19 | Sqz Biotechnologies Company | Wewnątrzkomórkowe dostarczanie biocząsteczek za pośrednictwem powierzchni z porami |
| JP7033535B2 (ja) * | 2016-01-12 | 2022-03-10 | スクイーズ バイオテクノロジーズ カンパニー | 複合体の細胞内送達 |
| AU2019234549B2 (en) * | 2018-03-12 | 2026-02-12 | Sqz Biotechnologies Company | Methods for treating HPV-associated diseases |
-
2019
- 2019-03-11 US US16/980,339 patent/US20240374654A2/en active Pending
- 2019-03-11 CN CN201980030600.3A patent/CN112135627A/zh active Pending
- 2019-03-11 SG SG11202008864VA patent/SG11202008864VA/en unknown
- 2019-03-11 EP EP19716612.7A patent/EP3765068A2/en active Pending
- 2019-03-11 CR CR20200460A patent/CR20200460A/es unknown
- 2019-03-11 KR KR1020207028580A patent/KR20200130835A/ko not_active Ceased
- 2019-03-11 JP JP2020548778A patent/JP7595827B2/ja active Active
- 2019-03-11 TW TW108108098A patent/TW202003019A/zh unknown
- 2019-03-11 AU AU2019234550A patent/AU2019234550B2/en active Active
- 2019-03-11 WO PCT/US2019/021705 patent/WO2019178006A2/en not_active Ceased
- 2019-03-11 MA MA052010A patent/MA52010A/fr unknown
- 2019-03-11 IL IL277188A patent/IL277188B2/en unknown
- 2019-03-11 MX MX2020009439A patent/MX2020009439A/es unknown
- 2019-03-11 BR BR112020018612-0A patent/BR112020018612A2/pt unknown
- 2019-03-11 CA CA3093828A patent/CA3093828A1/en active Pending
-
2020
- 2020-09-11 PH PH12020551436A patent/PH12020551436A1/en unknown
- 2020-11-03 CO CONC2020/0012584A patent/CO2020012584A2/es unknown
-
2024
- 2024-10-25 JP JP2024188260A patent/JP2025020210A/ja active Pending
-
2026
- 2026-03-03 AU AU2026201618A patent/AU2026201618A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021517813A5 (enExample) | ||
| JP2021517895A5 (enExample) | ||
| IL277188B1 (en) | Intracellular delivery of biomolecules to modify the immune response | |
| Quayle et al. | CUE-101, a novel E7-pHLA-IL2-Fc fusion protein, enhances tumor antigen-specific T-cell activation for the treatment of HPV16-driven malignancies | |
| von Bergwelt-Baildon et al. | Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application | |
| Shibagaki et al. | Dendritic cells transduced with protein antigens induce cytotoxic lymphocytes and elicit antitumor immunity | |
| US11377481B2 (en) | SpyCatcher and SpyTag: universal immune receptors for T cells | |
| JP7523203B2 (ja) | 生体分子の免疫細胞への送達 | |
| EP0914416B1 (en) | Method for the production of activated marked tumor-specific t cells and use thereof in treatment of tumors | |
| CN103898051B (zh) | 提高免疫反应性的方法 | |
| JP2022522351A5 (enExample) | ||
| Harmala et al. | The adjuvant effects of Mycobacterium tuberculosis heat shock protein 70 result from the rapid and prolonged activation of antigen-specific CD8+ T cells in vivo | |
| Grodeland et al. | DNA vaccine that targets hemagglutinin to MHC class II molecules rapidly induces antibody-mediated protection against influenza | |
| CN104411819A (zh) | 用于过继细胞疗法的改进的细胞培养方法 | |
| Batista-Duharte et al. | Immune checkpoint inhibitors for vaccine improvements: current status and new approaches | |
| CN104619723A (zh) | 评估用于施用的转导t细胞的适用性的方法 | |
| KR20170045205A (ko) | 감마 델타 t 세포 및 이의 용도 | |
| TW201247700A (en) | Immunoglobulin-like transcript (ILT) receptors as CD8 antagonists | |
| US12473342B2 (en) | Chimeric antigen receptor T regulatory cells for the treatment of atherosclerosis | |
| Kan-Mitchell et al. | The HIV-1 HLA-A2-SLYNTVATL is a help-independent CTL epitope | |
| JP2021515588A5 (enExample) | ||
| Gerloni et al. | T cell immunity using transgenic B lymphocytes | |
| JP2022514116A (ja) | 新規な癌抗原及び方法 | |
| JP2021527419A (ja) | 免疫細胞操作用の安定化されたｍｈｃ分子を有するスカフォールド | |
| JP2023539370A5 (enExample) |